Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 4/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | CBLB | Q13191 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29867073 | 0.94 | RBP4 (0.36) | RBP4SMYD3SLC6A3PDE4DCBLB | |
| SCHEMBL21200131 | 0.86 | SMYD3 (0.35) | RBP4SMYD3PDE4DCBLBCHRM3 | |
| SCHEMBL29867676 | 0.80 | OPRM1 (0.36) | RBP4SMYD3PDE4DCBLBCHRM3 | |
| SCHEMBL21200767 | 0.79 | KDM4E (0.48) | RBP4PDE4DCHRM3PDE4APDE4B | |
| SCHEMBL29867435 | 0.79 | KDM4E (0.48) | RBP4PDE4DCHRM3PDE4APDE4B | |
| SCHEMBL21200772 | 0.76 | RBP4 (0.46) | RBP4SLC6A3PDE4DCBLBKDM4E | |
| SCHEMBL21200526 | 0.72 | POLB (0.39) | RBP4SLC6A3PDE4DPLATKDM4E | |
| SCHEMBL21200027 | 0.71 | ALDH1A1 (0.49) | RBP4PDE4DKDM4EALDH1A1 | |
| SCHEMBL21199919 | 0.71 | RBP4 (0.44) | RBP4CBLBKDM5AKDM4EALDH1A1 | |
| SCHEMBL27271945 | 0.71 | PDE4D (0.40) | RBP4SLC6A3PDE4DKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | RBP4 3275/4885SMYD3 1442/4885SLC6A3 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.